Today: 30 June 2026
Lumentum (LITE) stock jumps near a new high — what traders are watching next week
4 January 2026
1 min read

Lumentum (LITE) stock jumps near a new high — what traders are watching next week

New York, Jan 4, 2026, 15:50 ET — Market closed

  • Lumentum ended Friday up 4.75% at $386.11, as U.S. stocks started 2026 with a rebound led by chip names.
  • The stock is about 4% below its 52-week high of $401.60 heading into Monday’s open.
  • Investors are looking to a heavy U.S. data week, capped by the government’s monthly jobs report on Jan. 9, and Lumentum’s next earnings update expected Feb. 5.

Lumentum Holdings shares rose 4.7% on Friday to close at $386.11, lifting the optical-components maker toward its highs as 2026 began. The stock last traded at that level in the regular session, with U.S. markets shut on Sunday.

The move matters because it leaves Lumentum extended into the first full week of January, when fresh economic data could sway rate expectations and risk appetite. Those macro swings have been moving “AI infrastructure” trades — the group that has helped power Lumentum’s run. Reuters

“Investors might be a little bit more conscious about the valuations that they’re paying for some of the AI plays,” Joe Mazzola, head of trading and derivatives strategist at Charles Schwab, told Reuters. Lumentum has been treated as part of that basket as it sells photonics — light-based components — used in communication networks and laser applications. Reuters

On Friday, chip stocks helped drive the broader bounce, with the Philadelphia SE Semiconductor index — a gauge of major chipmakers — up about 4%, Reuters reported. Lumentum climbed alongside other laser and optical names, including Coherent, IPG Photonics and nLIGHT.

The rally pushed Lumentum to within roughly 4% of its 52-week high of $401.60, with Friday’s trading range spanning $375 to $392. The stock also sits about a third above its 50-day moving average around $288, a widely watched trend indicator.

The next company catalyst on the calendar is earnings. Nasdaq and Zacks list Lumentum’s next report date as Feb. 5, when investors will be looking for demand and margin commentary to justify the stock’s elevated level.

Before that, traders will be watching the data pipeline. The ISM manufacturing PMI is due on Monday, typically released at 10:00 a.m. ET on the first business day of the month, while the U.S. Employment Situation report for December is scheduled for Friday, Jan. 9 at 8:30 a.m. ET.

But the setup cuts both ways. With valuations in focus and the stock near its highs, a hotter inflation or jobs read that pushes Treasury yields up could pressure high-momentum technology and AI-linked names, including optical-hardware suppliers.

For Lumentum, the immediate test is whether Friday’s risk-on bid holds when markets reopen Monday. The next clear catalysts are the Jan. 9 U.S. jobs report and Lumentum’s Feb. 5 earnings release.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Next Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

Go toTop